A “gold standard” trial found that semaglutide helped reduce drinking in people with obesity who sought out treatment for ...
A study published by Danish researchers on Friday suggests that semaglutide drugs like Wegovy and Ozempic can significantly ...
As more people take GLP-1s, many are experiencing side effects like hair loss. This is creating brand new opportunities for ...
A majority of GLP-1 lawsuits come from patients who allege that manufacturers have inadequately warned about severe side ...
Ashley Graham is the latest public figure to open up about the rise of GLP-1s for weight loss. In a The Ashley Graham ...
Company positions itself as the central research hub for patients, clinicians, and compounding pharmacies tracking the ...
The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 drugs for obesity in Medicare.
The unchanged US$9.88 fair value estimate for LifeMD keeps the core price target steady, even as model inputs see only marginal tweaks. That stability lines up with recent analyst debate around Q4 ...
Doctronic reports new AI analysis reveals GLP-1 medications may cause underreported symptoms like menstrual irregularities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results